Drug Discovery Featured Articles & Applications

  1. Eliminate The “Patchwork Quilt” Of Sample Management Systems
    5/23/2016

    This BIOVIA customer uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility associated with the world of biotech. The company focuses on a range of illnesses including cancer, cardiovascular disease, diabetes, hepatitis B, HIV/ AIDS, rheumatoid arthritis and psychiatric disorders. Their R&D organization prioritizes pipeline velocity and sales growth while continuing to manage costs.

  2. Best Practices For Chemical Inventory Management
    5/23/2016

    Companies that utilize chemicals in their labs and their manufacturing processes must manage those chemicals in a safe environment in accordance with government regulations. At a minimum, to ensure that this is accomplished, a system for managing information about the chemical safety and inventory data should be established and maintained. Best practices, on the other hand, take this minimum and leverage the management of the chemical inventory by taking full advantage of the people, processes, and technology involved. This white paper delves into the best practices involved in managing chemical inventory to achieve the most effective, holistic chemical inventory system.

  3. BIOVIA Chemical Inventory Management Customer Story
    5/23/2016

    AkzoNobel is a leading worldwide producer of decorative paints, performance coatings and specialty chemicals headquartered in Amsterdam, The Netherlands. They supply industries and consumers with innovative products in four key market segments: buildings and infrastructure, transportation, consumer goods and industrial applications. The company has approximately 50,000 employees in over 80 countries and more than 200 production sites.

  4. Exploring Collaboration With Third Parties And The Impact On Document Management
    5/18/2016

    The trend towards virtual pharma is accelerating and as it does, the life sciences industry is undergoing a profound structural change. The areas of development and commercialization which were once conducted within the confines of one company have now become a collaboration within an ecosystem of entities, both public and private.

  5. Vertex Pharmaceuticals: Document Management Strategies For R&D
    5/18/2016

    Based out of South Boston, MA, with additional research programs in the UK and Canada, Vertex Pharmaceuticals has spent the past 25 years working to improve the lives of patients with serious diseases.

  6. How To Avoid 5 LIMS Nightmares
    5/18/2016

    Traditional Laboratory Information Management System (LIMS) implementations are notorious for keeping people awake at night. Industry analysts like Strategic Directions and ARC Advisory Group have estimated the failure rate of commercial LIMS solutions to be as high as 60 percent with many of them failing to deliver original customer requirements after lengthy and expensive deployments.

  7. 7 Things To Know When Selecting An Electronic Lab Notebook
    5/18/2016

    Electronic lab notebooks (ELNs) are one of the primary scientific informatics solutions for helping scientists design, execute, analyze and report on experiments—but selecting the right ELN can be a challenge.

  8. Improve Operations, Collaboration, And Time-To-Market: The Digital Lab
    5/18/2016

    Many leading life sciences companies have introduced cost-reduction initiatives to automate routine, non-value-added tasks related to data capture, cataloguing and documentation activities as products move from discovery through development to late-stage quality control, manufacturing and commercial operations.

  9. Following FDA Guidance: Continuous Improvement In An Outsourced Environment
    5/18/2016

    In May 2013 the U.S. Food and Drug Administration (FDA) released its draft guidance, “Contract Manufacturing Arrangement for Drugs: Quality Agreements,” with recommendations representing its “current thinking on defining, establishing, and documenting the responsibilities of each party (or all parties) involved in the contract manufacturing of drugs subject to Current Good Manufacturing Practice (CGMP). In particular, we describe how parties involved in the contract manufacturing of drugs can utilize Quality Agreements to delineate their responsibilities and assure drug quality, safety, and efficacy.”

  10. The New Strategic CDMO: Bringing End-to-End Solutions for Better and Faster Drug Development
    5/17/2016

    Bill Weiser, executive director and global head of analytical sciences at Patheon, discusses how a new generation of CDMOs have positioned themselves to provide more strategic solutions that not only complement product development but also drive therapies to patients faster.